Low-Dose Clarithromycin Therapy Modulates Th17 Response In Non-Cystic Fibrosis Bronchiectasis Patients

Abstract

Our results argue for a reduction of both systemic and local Th17 response after prophylactic, low-dose clarithromycin administration in patients with non-CF bronchiectasis, suggestive of a potential anti-inflammatory and/or immunomodulatory action.

The heterogeneity of systemic inflammation in bronchiectasis

“…IL-17 has a key role in inducing 16 and mediating pro-inflammatory responses [14]. exacerbations in bronchiectasis [17][18][19]) have been shown to reduce IL-17 expression in patients with bronchiectasis [20].…”

Pulmonary Hypertension and Noncardiac Surgery: Implications for the Anesthesiologist—Additional Considerations

“…That study included few patients. 3 Thus, the preoperative use of airway clearance techniques in the present patient report is feasible and constitutes a safe option to facilitate sputum expectoration. 4 Patients with pulmonary hypertension have predictable increased risk of perioperative morbidity and mortality.…”

Macrolide Therapy and Alveolar Hemorrhage Secondary to Granulomatosis With Polyangiitis

“…Experimental and clinical studies show that macrolides cause increased leucocyte apoptosis, reduced cytokine expression, and impaired T-cell proliferation and signalling [11]. Administration of oral clarithromycin to patients with bronchiectasis has been shown to cause local and systemic modulation of the Th17 axis [12], which has also been implicated in the pathogenesis of AAV [13]. Tacrolimus and rapamycin (sirolimus) are non-antimicrobial macrolides widely used in transplantation medicine.…”